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Abstract
Background: Journal advertising is one of the main sources of medicines information to doctors. Despite the availability of
regulations and controls of drug promotion worldwide, information on medicines provided in journal advertising has been
criticized in several studies for being of poor quality. However, no attempt has been made to systematically summarise this
body of research. We designed this systematic review to assess all studies that have examined the quality of pharmaceutical
advertisements for prescription products in medical and pharmacy journals.
Methods and Findings: Studies were identified via searching electronic databases, web library, search engine and reviewing
citations (1950 – February 2006). Only articles published in English and examined the quality of information included in
pharmaceutical advertisements for prescription products in medical or pharmacy journals were included. For each eligible
article, a researcher independently extracted the data on the study methodology and outcomes. The data were then
reviewed by a second researcher. Any disagreements were resolved by consensus. The data were analysed descriptively. The
final analysis included 24 articles. The studies reviewed advertisements from 26 countries. The number of journals surveyed
in each study ranged from four to 24 journals. Several outcome measures were examined including references and claims
provided in advertisements, availability of product information, adherence to codes or guidelines and presentation of risk
results. The majority of studies employed a convenience-sampling method. Brand name, generic name and indications were
usually provided. Journal articles were commonly cited to support pharmaceutical claims. Less than 67% of the claims were
supported by a systematic review, a meta-analysis or a randomised control trial. Studies that assessed misleading claims had
at least one advertisement with a misleading claim. Two studies found that less than 28% of claims were unambiguous
clinical claims. Most advertisements with quantitative information provided risk results as relative risk reduction. Studies
were conducted in 26 countries only and then the generalizability of the results is limited.
Conclusions: Evidence from this review indicates that low quality of journal advertising is a global issue. As information
provided in journal advertising has the potential to change doctors’ prescribing behaviour, ongoing efforts to increase
education about drug promotion are crucial. The results from our review suggest the need for a global pro-active and
effective regulatory system to ensure that information provided in medical journal advertising is supporting the quality use
of medicines.
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Introduction
Advertising in medical journals is one of the techniques used by
pharmaceutical companies to promote their products to medical
doctors. During the first four years of a new medicine on the
market, pharmaceutical companies may gain approximately US
$2.43 for each dollar spent on medical journal advertisements for a
medicine [1]. The return on investment has been reported to
increase to more than US $4 after that period [1].
Doctors use advertising in medical journals as one of the main
sources of information for newly marketed drugs [2,3,4,5]. Therefore,
ideally, information provided in advertisements should be of high
quality to support doctors to practice evidence-based medicine.
Internationally, two sets of guidelines have been developed for
pharmaceutical advertising. In 1988, the World Health Organi-
zation (WHO) established the Ethical criteria for medicinal drug
promotion [6]. These criteria constitute general principles for
ethical standards that can be adapted by governments to national
circumstances. The International Federation of Pharmaceutical
Manufacturers Association (IFPMA) has adopted a Code of
Pharmaceutical Marketing Practices, supplemented by member
association and company codes, that sets standards for the ethical
promotion of medicines [7]. It is a requirement of IFPMA
membership that member associations adopt codes that meet local
requirements but are consistent with, and as comprehensive as, the
IFPMA Code. The IFPMA seeks to ensure that ethical
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6350
promotional practices are established worldwide. These guidelines
provide recommendations on the type and quality of information
that should be included in journal advertisements. In most
countries, regulation of the quality of advertisements in medical
journals is a responsibility of government agencies [8] and/or the
pharmaceutical industry [9]. Pharmaceutical industry codes of
conduct most often complement the requirements set in legislation
by developing standards and investigating alleged breaches [9].
Despite the availability of regulations and controls of drug
promotion worldwide, pharmaceutical advertising in medical journals
has been criticized for being of poor quality [10,11,12,
13,14,15,16,17,18,19,20,21,22]. Several studies have assessed the
quality of pharmaceutical advertisements and examined a range of
different outcome measures [10,11,12,14,17,18,20,22,23,24,25,26,
27,28,29,30,31,32,33] such as availability of product information
[14,29,30,31], type and truthfulness of marketing claims [20,24],
quality and availability of references provided to support the claims
[19,34], presentation of scientific results in terms of absolute or relative
risk reductions [17,20], quality of graphs [12] and overall compliance
with the national regulations or guidelines [10,11]. The overall results
of these studies have never been synthesized. A systematic review
would provide researchers and policy makers with information on the
standards of pharmaceutical advertisements that may reflect the
effectiveness of current guidelines and regulations.
We aimed to do a systematic review of all studies that have
examined the quality of pharmaceutical advertisements for
prescription products published in medical and pharmacy journals.
Methods
Selection Criteria
Studies were included in the review if they were published in
English and examined the quality of information included in
pharmaceutical advertisements for prescription products in
medical or pharmacy journals. Studies were excluded from the
review if they met one of the following conditions:
– only evaluated advertisements provided in pamphlets, bro-
chures, leaflets and inserts. Unlike advertisements in medical
journals, there is no repository of pamphlets, brochures and
others which makes it very difficult to collect appropriate and
representative samples for a study.
– assessed advertisements for both prescription and non-pre-
scription medicines without separating the results,
– assessed advertisements for both prescription medicines and
medical devices without separating the results,
– only assessed gender, metaphors or race issues in advertisements,
– assessed outcomes that were not related to the quality of
medical information such as the use of pharmaco-economic
terms and patterns of advertising.
Search Strategy
We searched Medline (from 1950), International Pharmaceu-
tical Abstracts (from 1970), Current Contents (from 1998), Scopus,
Sociological Abstracts (from 1952), PsychInfo (1950) and Business
Source Complete (from 1950). We also searched the Drug
promotion database [35], Google Scholar, Web of Science (from
1993), and the Healthy Skepticism web library [36]. The first 100
results returned by each search from the Google Scholar were
scanned for relevant articles.
We searched the databases for all studies published up to February
2006. The following combinations of search terms were used:
‘‘pharmaceutical’’, ‘‘advertising or advertisements’’, ‘‘promotion’’,
‘‘codes of conduct’’, ‘‘medical journal’’, ‘‘marketing’’,’’ journal’’,
‘‘physicians’’ and ‘‘quality’’ and ‘‘information’’. One researcher
carried out the search and scanned the title and abstracts of studies
identified from this search. A copy of all articles potentially eligible
was retrieved and screened by the same reviewer for the inclusion
criteria. All bibliographies of selected papers were screened for
additional relevant articles.
Data Extraction
Data extraction forms were developed to collect data on study
design and study outcomes. For each eligible article, a researcher
extracted the data. A second researcher then reviewed the data.
All disagreements were resolved by consensus.
Information extracted on study design included: sampling
methodology, total number of advertisements surveyed, total
number of distinct advertisements surveyed, number of reviewers,
consistency of reviewers, year of publication, period and country
studied, type and number of journals evaluated.
The outcome measures examined included the availability of
product information, the quality and availability of the references,
the presentation of the risk results and the nature and quality of
promotional claims.
Availability of Product Information
We extracted the proportion of advertisements that included
information on brand name, generic name, indications, side
effects, dosage, interactions, precautions and contraindications,
warnings and treatment of overdose.
References
We examined information on references including the propor-
tion of advertisements that used references, types of references
provided to support marketing claims, quality of references, source
of research funding of references and response from pharmaceu-
tical companies to a requests for data on file.
Claims
We extracted information on number and type of claims,
number of misleading claims and proportions of advertisements
compliant with codes or guidelines.
Risk Results
We extracted proportions of advertisements mentioning relative
risk reduction (RRR), absolute risk reduction (ARR) and number
needed to treat (NNT).
Data Analysis
As studies calculated results differently either on the basis of the
total number of advertisements or on the total number of distinct
advertisements (similar advertisements may be repeated in
journals), we recalculated the results based on the total number
of distinct advertisements when the raw data were available.
Data were entered using Microsoft Office Excel 2003.
Descriptive statistics were produced for each outcome. A narrative
synthesis method was used to enable us to analyse a large and
diverse evidence base.
Results
Fifty articles were identified and 24 were included in the systematic
review (Table 1) [10,11,14,15,17,18,19,20,21,22,24,26,27,28,29,
30,31,34,37,38,39,40,41,42]. Twenty-six studies [3,13,23,25,33,43,
44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63] were
excluded after full review. The reasons for exclusion are detailed in
the study flow diagram in Figure 1.
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Characteristics of Studies Included
The studies reviewed advertisements from 26 countries
predominantly the United Kingdom (UK) (7/24, 29%), Australia
(5/24, 21%) and the United States (US) (4/24, 17%) (Table 1).
Most studies (19/24, 79%) assessed the quality of advertisements
in developed countries. All studies were cross-sectional studies.
All studies were published between 1975 and February 2006.
Five studies (5/24, 21%) were published between 1975 and 1990,
Table 1. General Characteristic of Studies.
Study (First
author) Country surveyed
Year of
publication
Number of
journal
examined
Period
studied
Number of
advertisements
Number of distinct
advertisements Sampling method
Lexchin [24] Canada 1999 5 1998 571 130 Convenience sample
Lankinen [17] Finland 2004 4 2002 1036 245 Convenience sample
Carandang [10] Australia 1994 4 1991 and 1992 Not reported 127 Convenience sample
Vlassov [31] Russia 2001 5 1998 397 207 Convenience sample
Chirac [11] French speaking African
countries (West African and
Maghreb)
1993 6 1990 1311 141 Convenience sample
Cooper [19] The US 2005 10 1999 Not reported 438 Convenience sample
Study (First
author) Country surveyed
Year of
publication
Number of
Journal
Period
studied
Total
advertisements
Number of distinct
advertisements Sampling method
Gilad [37] Israel 2005 24 2000 779 Not reported Convenience sample
Gitanjali [38] India and Britain 1997 2 1992 and 1993 203 Not reported Convenience sample
Lal [39] India 1992 19 1990–1991 903 Not reported Convenience sample
Stimson [34] The UK 1976 19 1974 1104 89 Convenience sample
Moulds [28] Australia 1987 5 (results only
given for 3)
1986 274 Not reported Convenience sample
Study
(First author) Country surveyed
Year of
publication
Number of
Journal
Period
studied
Total
advertisements
Number of distinct
advertisements Sampling method
Herxheimer [14] 18 countries. (Finland,
Norway, Sweden, Denmark,
Spain, France, Italy, Ireland,
UK, Switzerland, Turkey,
Indonesia, Nepal, Pakistan,
Sri Lanka, Tanzania,
Zimbabwe and Brazil)
1993 23 1987 to 1988 6710 No reported Convenience sample
Mastroianni [30] Brazil 2003 4 1985 to 2001 Not reported 199 Convenience sample
Villanueva [22] Spain 2003 6 1997 954 287 Convenience sample
Study (First
author) Country surveyed
Year of
publication
Number of
Journal
Period
studied
Total
advertisements
Number of distinct
advertisements Sampling method
Stimson [42] The UK 1975 27 1974 3895 591 Convenience sample
Mould [26] Australia 1986 5 1985 Not reported 138 Convenience sample
Mindell [40] UK 1997 1 1997 Not reported 46 Convenience sample
Wilkes [15] The US 1992 10 1990 143 109 Convenience sample
Lal. [29] India, UK and the US 1997 Not reported From July 1994
to June 1995
Not reported 762 Random sample
Study (First
author) Country surveyed
Year of
publication
Number of
Journal
Period
studied
Total
advertisements
Number of distinct
advertisements Sampling method
Loke [20] Australia 2002 6 Oct to Dec 2000 1000 174 Convenience sample
Gutknecht [21] The US 2001 4 1999 Not reported 187 Convenience sample
Lexchin [18] Canada 1994 1 1990 Not reported 22 Convenience sample
Moulds [27] Australia 1989 1 1988 56 Not reported Convenience sample
Smart [41] The UK 1997 1 1996 Not reported 81 Convenience sample
doi:10.1371/journal.pone.0006350.t001
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eleven (11/24, 46%) between 1990 and 2000 and eight (8/24,
33%) between 2000 and 2005.
The studies were conducted with three main objectives. Four
studies (4/24, 17%) compared the quality of advertisements
in different countries. Sixteen studies (16/24, 67%) assessed the
quality of advertisements in a single country. Five studies (5/24,
21%) compared advertisements published at different times
[10,26,27,28,30]. Four of the five studies conducted in Australia
used the same methodology and three of these were done by
the same researchers enabling comparison overtime [10,26,
27,28].
Twenty-three studies surveyed advertisements in medical
journals and one study assessed advertisements in medical and
paramedical journals. The number of journals surveyed in each
study ranged from one to 24 journals. Eighteen studies (18/24,
75%) provided information on the total number of distinct
advertisements analyzed. Nine studies (9/24, 38%) reported both
the total number advertisements and number of distinct
advertisements examined in their studies. The total number of
advertisements evaluated ranged from 56 to 6710 (median= 903)
and the number of distinct advertisements ranged from 22 to 762
(median = 158).
Several types of outcome measures were examined (Table 2).
Sixteen studies (16/24, 67%) assessed references provided in
advertisements, nine studies (9/24, 38%) examined availability of
product information and nine studies (9/24, 38%) assessed claims
provided in advertisements. Four studies (4/24, 17%) evaluated
presentation of risk results and seven studies (29%) assessed
adherence to codes or guidelines.
Study Quality
Seventeen studies (17/24, 71%) provided data on the number of
assessors. Three studies (3/24,13%) used one assessor, eight studies
(33.3%) used two assessors and five studies (2/24, 21%) used
between three to five assessors. One multi-country study had
different assessors per country [14] who may have applied different
standards. Five studies (5/24, 21%) provided information on the
consistency of assessors. Of the three studies (3/24, 12%) that
reported kappa scores, good and excellent agreement was noted.
Twenty-three studies (23/24, 96%) used a convenience-
sampling method. Six studies (6/24, 25%) selected journals based
on readership [14,15,18,22,24,31]. One study (1/24, 4%) used
random sampling but no information was given on how the
randomization was conducted [29].
Figure 1. Literature Search and Study Selection.
doi:10.1371/journal.pone.0006350.g001
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Availability of Product Information
Six of the eight studies (6/24, 25%) that recorded information
on generic name found that generic names were mentioned in 83
to 100% of advertisements (median = 90%) (Table 3). A UK study
in 1975 [42] and a Russian study in 2001 [31] found lower rates,
43% and 39% respectively.
Approved indications were mentioned in more than 70%
(median = 94% ) of advertisements in five studies [11,14,
29,30,39]. Lower rates were observed in the Russian study
(45%) [31] and in some countries (Italy, 34%, Tanzania, 40%) in a
multi-country study [14]. Six studies (6/24, 25%) that examined
information on side effects reported mixed results [11,14,29,
30,39,42]. Five studies (5/24, 21%) reported low rates of
information, around 14% or less (median= 6%) in India [29,39],
Finland [14], Switzerland [14] and in an 1975 UK study [42].
Two studies (2/24, 8%) published in 1993 and 1997 reported rates
over 80% (median= 83%), namely in the US [29], Denmark [14],
Spain [14], France [14] and the UK [14,29].
Studies that examined information on contraindications
[11,14,29,30,31,39,42], warnings [14,29,30,31,39], precautions
[14,29,39,42] reported variable findings. Six studies (6/24, 25%)
that reported information on contraindications found that
contraindications were mentioned in less than 74% (medi-
an = 35%). Two studies (2/24, 8%) reported that contraindications
were mentioned in 82 to 93% (median= 88) of advertisements in
Denmark [14], Spain [14], the UK [14,29] and the US [29].
Information on warnings was mentioned in less than 77%
(median= 35%) of advertisements in five studies (5/24, 21%).
One study reported that warnings were mentioned in 80 to 95%
(median= 83%) of advertisements namely in Spain [14], France
[14], and the UK [14]. Four studies that reported information on
precautions found that precautions were mentioned in less than
65% (median= 32%). Two studies (2/24, 8%) reported that
precautions were mentioned in 80 to 95% (median= 83) of
advertisements in Spain [14], France [14], the UK [14,29] and the
US [29].
Five studies (5/24, 21%) reported information on dosage (range:
14–100%, median = 80%) [11,29,30,39,42]. High results were
noted in advertisements that appeared in the UK from July 1994
to June 1995 (97%) [29] and in West African and Maghreb in
1990 (87%) [11]. Variable findings were noted before and after the
implementation of regulations on advertisements in a study
conducted in Brazil in 2003 (range= 58–100%, median= 83% )
[30]. Two Indian studies [29,39] conducted in different years
revealed different results [38].The study that was conducted in
1997 [29] found much lower (31%) information on dosage
compared to the earlier study in 1992 (73%) [39].
References
References were provided in more than half of the advertisements
(range 51–100%, median= 65%) in all studies that evaluated
advertisements in developed countries [15,17,19,29,34,37,40,41]
except a study published in Spain (13%) [22] (Table 4). References
were more rarely provided (range 2–59%, median= 23%) in
Table 2. Outcome Measures.
Outcome measure(s) Study (First author) Number of studies
Product information
Availability Carandang [10], Vlassov [31], Chirac [11], Gitanjali [38], Lal [39], Mastroianni [30],
Herxheimer [14], Lal [29], Stimson [42].
9
References
Availability of references Lankinen [17], Carandang [10], Vlassov [31], Cooper [19], Gilad [37], Lal [39],
Stimson [34],Smart [41], Herxheimer [14], Mastroianni [30], Villanueva [22],
Mindell [40], Wilkes [15], Lal [29]
14
Type of references Carandang [10], Cooper [19], Stimson [34], Smart [41], Villanueva [22], Mindell [40],
Lexchin [18], Herxheimer [14],
8
Quality of references Lankinen [17], Villanueva [22], Loke [20], Mindell [40], Smart [41], Lexchin [18],
Stimson [34]
7
Type of outcomes measure in references Villanueva [22] 1
Availability of information on sponsorship Stimson [34], Villanueva [22], Cooper [19] 3
Claims
Number of marketing claims with reference Lankinen [17], Villanueva [22] 2
Number of advertisements with medical claims Villanueva [22] 1
Type of claims Lankinen [17], Loke [20], 2
Validity of claims Gitanjali [38], Moulds [28], Villanueva [22], Moulds [26], Herxheimer [14],
Wilkes [15], Moulds [27]
7
Risks results
Methods of presentation of risk results Lexchin [24], Lankinen [17], Loke [20], Gutknecht [21] 4
Adherence to codes or guidelines
Compliance with codes or guidelines. Carandang [10], Chirac [11], Moulds [28], Mastroianni. [30], Moulds.[26],
Wilkes [15], Moulds [27]
7
Response provided by pharmaceutical
companies upon a request for references
Response upon a request for references Stimson [34], Lexchin [18], Cooper [19], Lal [39] 4
doi:10.1371/journal.pone.0006350.t002
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developing countries [29,30,31,39]. Three studies (3/24, 12%)
[17,20,22] found that between 18 to 37% (median= 32%) of
references supporting claims were irretrievable.
Type of References
Eight studies (8/24, 33%) assessed the type of references provided in
pharmaceutical advertisements. Overall, the references most com-
monly cited were journal articles (range=55 to 90%, median=73%).
Other types of evidence were data on file (range=15–19%,
median=17%) [10,14,19], meeting abstract and presentations
(range=5–23%, median=15%) [19,22,40], books or monographs
(range=5–18%, median=8%), marketing reports (5%) [19], pre-
scribing information (range=6–20%, median=13% ) [19,40],
government documents (4%) [19], and other evidence (1%).
References - Source of Research Funding
Three studies (3/24, 12%) examined the funding of studies used
in references (range= 39–58%, median= 40%) [19,22,34]. A
study that was conducted in the US determined that the majority
(58%) of the original research cited in the pharmaceutical
advertisements was sponsored by or had an author affiliated with
the product’s manufacturer [19]. A Spanish study [22] found that
41 studies (40%) had been financed by the pharmaceutical
industry. Similar findings were noted in a UK study of which 39%
of references were sponsored by the industry [34].
Response to Request for Data on File
Three studies (3/24, 12%) investigated how companies
responded to request for data on file [18,19,39]. The response
rates were 42%[19], 37% [39] and 60% [18].
Quality of References
Of seven studies (7/24, 29%) [17,18,20,22,34,40,41] that
examined the quality of references, four studies (4/24, 17%)
[17,20,22,41] assessed the level of evidence of the references cited
to support marketing claims (Table 5). One to twelve percent of
references (median= 2%) were supported by a systematic review
or meta-analysis. More randomised control trials were cited in a
Spanish study (67%) compared to studies published in the UK
(30%), Finland (9%) and Australia (35%).
Three studies (3/24, 12%) examined other aspects of the quality
of the references [18,34,40]. A UK study [40] found that only two
fifths of advertisements cited were published, peer reviewed
references. A Canadian study found that the mean methodological
quality score (58%, 95% CI 51%–65%) and the mean relevance
score (76%, 95% CI 72%–80%) of the references were
significantly lower than the acceptable score of 80% (p,0.05)
[18].The poor rating for methodological quality was primarily
because of the citation of references to low-quality review articles
and ‘‘other’’ sources [18]. A UK study [34] assessed whether the
claims were supported by adequate references. Of 49 references
cited to substantiate the claims, 14 (29%) were judged adequate on
the basis of predetermined criteria including presence of adequate
controls, randomisation of treatments, objective assessment and
statistical analysis of results.
Type of Claims
One study in Australia (2002) [20] and one in Finland (2004)
[17] (2/24, 8%) used the same system to classify the claims
provided in advertisements. Nine to 28% of the claims were about
an unambiguous clinical outcome, 29 to 37% provided a vague
clinical outcome, 20 to 31% an emotive or immeasurable outcome
and 23% a non-clinical outcome.
Validity of Claims
Seven (7/24, 29%) studies examined the validity of promotional
claims [10,14,15,26,27,28,38]. Four Australian studies in 1986
[26],1987 [28],1989 [27] and 1994 [10] examined the proportion
of misleading claims in Australian advertisements. Thirty-one
percent of advertisements reviewed in 1986 and 1987 were judged
to be misleading and 16% in 1989. A third study in 1994 with the
Table 4. Availability of References.
Study (First author)
Number of advertisements
with references n (%)
Mindell 1997 [40] 31/46 (67)
Lankinen 2004 [17] 245/245 (100)
Cooper 2005 [19] 312/438 (71)
Stimson 1976 [34] 89/89 (100)
Smart 1997 [41] 41/81 (51)
Mastroianni 2003 [30] * 6/39 (15), 7/31 (23)
8/19 (42), 9/19 (47)
33/60 (55), 20/34 (59)
Villanueva 2003 [22] 38/287 (13)
Wilkes 1992 [15] 69/109 (63)
Study (First author)
Number of advertisements
with references n (%)
Vlassov 2001 [31] 8/397 (2)
Gilad 2005 [37] antibiotics/other drugs (56) and (52)
Lal 1992 [39] (5)
Herxheimer 1993 [14] (20)
Lal 1997 [29] (19), (68), (51)
*Advertisements published before and after 3 regulation were established.
doi:10.1371/journal.pone.0006350.t004
Table 5. Level of evidence.
Study (First author) Level of evidence n (%)
Systematic review or Meta analysis Randomized control trial Other evidence
Smart et al, 1997 [41] 2/139 (1) 41/139 (30) 96/139 (69)
Lankinen et al, 2004 [17] 9/381 (2) 33/381 (9) 135/381 (36)
Loke et al, 2002 [20] 99/855 (12) 297/855 (35) 75/855 (9)
Villanueva et al, 2003 [22] - 84/125 (67) 18/125 (14)
doi:10.1371/journal.pone.0006350.t005
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same methods but a different principal investigator classified 8% of
advertisements as misleading [10].
In a study [38] conducted in India, ten randomly selected
advertisements from the Indian edition of British Medical Journal
were sent to three experts. They found that all the advertisements
were misleading or made unsubstantiated claims [38]. One multi-
country study with a different evaluator in each country [14] found
that relatively few (no detailed information provided) advertise-
ments provided misleading information except in Brazil (25%),
Finland (50%), Italy (30%) and Pakistan (38%). However, no
definition of misleading information was given [14].
In 1992, an American study [15] reviewed 109 advertisements
published in 10 medical journals and noted that headlines were
found to mislead the reader about efficacy in 32% of advertise-
ments. In 44% of cases, reviewers felt that the advertisement
would lead to improper prescribing if the physician had no other
information about the drug other than the advertisement [15].
A Spanish study [22] found that 44% of claims with citations
were not supported by the reference, most frequently because it
recommended the drug for a patient group other than that
assessed in the study.
Presentation of Risk Results
Four studies (4/24, 17%) reported information on how benefit
and harm were presented in advertisements that reported changes
in clinical outcomes (Table 6) [17,20,21,24]. Between 7 and 22%
(median= 7%) of advertisements provided information on risk
results [20,24]. In a Canadian study [24], half of the 22
advertisements that reported changes in clinical outcomes reported
the RRR, none reported the ARR or NNT, but 41% provided data
that would enable readers to calculate those figures if they knew
how. In an Australian study [20], none of the claims explicitly
reporting quantitative outcomes provided ARR or NNT. In two
other studies, none of the advertisements provided NNTs [17,21].
Discussion
We found that pharmaceutical advertisements in medical
journals usually provided brand and generic name and indication.
Other essential information required for rational prescribing
including contraindications, interactions, side effects, warnings
and precautions were less commonly provided. The majority of
references cited to support pharmaceutical claims were journal
articles. However, less than two-third of the claims were supported
by a systematic review or a meta-analysis (110/1375, 8%) and
randomised control trial (455/1500, 30%). About half of
references were sponsored or had researchers affiliated with
pharmaceutical companies. Pharmaceutical companies often did
not provide data on file when requested. Variable rates regarding
misleading claims were noted. Only 28% or less of claims were
unambiguous clinical claims. When presented, most advertise-
ments provided information on risk results as RRR not as ARR
and NNT.
Provision of balanced drug information is a necessary element
in the promotion of the appropriate use of medicines. Doctors
need to be informed about the benefits but also the risks of drugs.
However, pharmaceutical companies’ efforts in providing bal-
anced information are debatable [13,64]. A US congressional
inquiry reported that from August 1997 to August 2002, the Food
and Drug Administration (FDA) issued 88 letters accusing drug
companies of advertising violations mainly because pharmaceuti-
cal companies overstated the effectiveness of their products [65].
Similarly, this review found that the negative effects of a drug,
which may discourage use of that drug, less commonly appeared in
advertisements. The IFPMA code serves as a model for individual
country marketing codes. While it states that promotional
information should be balanced, it appears that the concept of
‘‘balanced information’’ is not clear [7]. There appears to be no
appropriate standard of balanced information. Therefore, clear
definition on balanced information appearing in pharmaceutical
advertisements should be determined. Future policies and
regulations on journal advertising need to take account of this
imbalance in information.
This review noted that references used to support pharmaceu-
tical claims were often of low quality. The inappropriate use of
references in journal advertising suggests that the availability of
references does not always guarantee the quality of claims.
Furthermore, current requirements of the IFPMA code of conduct
on the use of references to support promotional claims is vague
and open to abuse [7]. This review suggests that the IFPMA
should strengthen its code by providing explicit requirement on
scientific evidence that may facilitate the selection of appropriate
references to support claims in journal advertising.
Our review noted that all studies that assessed misleading claims
had at least one advertisement with a misleading claim. The results
call into question the commitment of pharmaceutical companies to
educate doctors about their products in order to establish a clear
understanding of the appropriate use of prescription medicines [7].
This review also highlights the limitation of the IFPMA code
which does not have a clear procedure to correct misleading
claims in journal advertising [7]. Furthermore, assessment of the
validity of promotional claims is difficult, this review lend support
to calls for increased education about drug promotion [66].
This review found that when presenting quantitative results,
journal advertising often provided information on risk results only
as RRR. As incomplete presentation of quantitative data may
influence doctors’ prescribing behaviour [67], this review call into
question the adequacy of the IFPMA code of conduct. According
to section 4 (2) of the code: ‘‘Promotional information should be clear,
legible, accurate, balanced, fair, objective and sufficiently complete to enable the
Table 6. Risk Results’ Information.
Study (First author) Advertisements with n (%)
Relative risk reduction Absolute risk reduction Number needed to treat
Original data permitting calculation by
readers
Lexchin 1999 [24] 29/130 (22) 0 (0) 0 (0) 9/130 (7)
Lankinen 2004 [17] No reported 1/245 (0.4) 0/245 (0) Not reported
Loke 2002 [20] 13/174 (7) 0 (0) 0 (0) 2/174 (1)
Gutknecht 2001 [21] Not reported Not reported 0 (0) Not reported
doi:10.1371/journal.pone.0006350.t006
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recipient to form his or her own opinion of the therapeutic value of the
pharmaceutical product concerned. Promotional information should be based on
an up-to-date evaluation of all relevant evidence and reflect that evidence
clearly. It should not mislead by distortion, exaggeration, undue emphasis,
omission or in any other way. Every effort should be made to avoid ambiguity’’.
The code does not provide any detailed requirements on how
quantitative results should be presented. This limitation highlights
the need for IFPMA to amend its code with regards to the
presentation of statistical information in journal advertising in
order to support the quality use of medicines
Information on medicines is essential to help doctors ensure the
optimal use of medicines. However, studies show that doctors who
use journal advertisements as a source of information may
prescribe less appropriately [68,69]. In addition, reliance on
journal advertising for information is associated with increased
costs of prescribing [70,71]. Even doctors who think that they
obtain their knowledge from the scientific literature can be
influenced by promotional sources without being aware of it [72].
As information provided in journal advertising has the potential to
change doctors’ prescribing behaviour, our review indicates that
ongoing efforts including complaints and recommendations by
researchers, health professionals and policy makers to improve the
quality of advertisements in medical journals are crucial.
The Ethical Criteria for Medicinal Drug Promotion developed
by the World Health Organization (WHO) [6] recommend a
minimum set of medicines information for journal advertising.
However, this review found that safety information was still
missing in studies undertaken after the publication of the WHO
Ethical Criteria. Since 1988, the WHO has not reviewed the
ethical criteria concerning advertising in medical journals [6].
Since the criteria lay the foundation for behaviour concerning the
pharmaceutical promotion, it may be necessary for WHO to be
proactive in updating the requirements for these activities.
Journal advertising is typically governed through self-regulatory
codes administered by industry associations. In most countries, the
recognition of breaches is based on a complaints mechanism.
Complaints of violations can only be made after advertisements
have already been circulated. The current system is limited by
retrospective detection of code breaches and has no prevention
focus. Furthermore, there is evidence that many violations of
marketing codes go unreported [73,74] and only a small portion of
promotional materials voluntarily submitted for comment before
submission are reviewed [75]. The poor quality of information
found in this review suggests that the current system may be
unable to regulate journal advertisements effectively. This
limitation highlights the need for governments and pharmaceutical
industry to be jointly responsible for regulating journal advertising.
Governments may need to take more proactive action such as
engaging independent experts to help in designing regulation for
journal advertising where self regulatory codes are limited. In
addition to that, effective regulatory system may complement
pharmaceutical litigation to ensure accuracy and reliability of
information in journal advertising [76].
Most medical journals rely on advertising for part of their
revenue. Dependence on revenue from the industry may minimize
the independence of the medical journals [77,78]. A survey in
North American survey found that 21% of journals editors
claimed that they did not review advertisements provided by the
industry before their appearance in the journals [79]. The low
quality of information provided in journal advertising noted by this
review highlight the need of journal editors and publishers to
consider regulatory controls for advertising in their publications.
Introduction of journal own codes is expensive. Journals obviously
need to have independent financial resources to remove the
conflict of interest with pharmaceutical companies. The Public
Library of Science (PLoS) [80], a non-profit scientific and medical
publisher has provided a good model which can be copied by
other journals. Sources of revenue for PLoS includes donations
from individual, paid individual memberships, support from
foundations, from institutional memberships, and from asking
research funders to pay a publication charge for accepted research
papers. In addition to that, medical journals’ financial resources
could be relied on the advertising of products other than those
supplied by pharmaceutical companies [77].
Our review found that the low quality of journal advertising was
a global issue. Poor quality advertising has been observed in
developing countries and post-Soviet Russia where controls might
be weak and limited as well as in developed countries which have
stricter regulations [81]. IFPMA states that the industry has an
obligation and responsibility to establish a clear understanding of
the appropriate use of prescription medicines. Based on the results
of this review, stronger enforcement mechanisms would appear
necessary to encourage pharmaceutical companies to provide
reliable information which is essential for the rational prescribing
of promoted products as recommended by the code. This is
particularly the case in developing countries and post-Soviet
Russia where independent sources of information on medicines
are limited and where doctors rely on industry for most medicine
information [82,83].
This systematic review provides the current body of evidence on
the quality of advertising in medical journals which will assist
researchers in designing future studies. However, the variability in
outcomes utilised in assessing the quality of information in the
studies made collation of results difficult. There appears to be no
consensus among researchers on the most appropriate outcomes.
Most studies assessed references, availability of product informa-
tion and adherence to codes or guidelines as indicators for
information quality. Pharmaceutical companies may provide
advertisements adhering to guidelines and with complete infor-
mation supported by strong research based evidence. However,
this does not mean that the advertisements are supporting rational
prescribing. There is a need for developing more appropriate
indicators to assess the quality of information in advertisements.
This effort will minimize the heterogeneity of data and will allow
direct comparison between studies.
Limitations
This review was limited to studies that had been published in
English language. Excluding studies in other languages may have
led to the omission of some studies that provide evidence about the
quality of information in journal advertising.
No attempt was made to define what was meant by quality of
information. Rather than entering into discussion regarding the
definition of the quality, we decided to define it based on presence
or absence of information, availability and level of evidence of
references, type and number of misleading claim and proportion
of advertisements compliant with code or guidelines and the
presentation of risk results.
Only one of the 24 studies included in this review selected
advertisements randomly and the report of that study did not
specify the random selection procedure. Also the countries studied
are not representative of all countries. Consequently extrapolation
of the average findings of this review to the average for all
advertisements around the world may not be accurate. The
number of studies is too small and their methods and quality are
too variable to allow confident overall conclusions about changes
over time or differences between countries.
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Future Work
This review has noted several outcomes measures that have not
been adequately investigated in research during the review period.
Firstly, only one study assessed whether claims were supported by
references [22]. Additional research on the use the references to
support claims in journal advertising is needed. Secondly, the
majority of studies that examined misleading claims were not well
reported [10,14,26,27,28,38]. Although it is difficult to judge
misleading claims, this review demonstrates the need for
development of a widely accepted definition of a misleading claim
and development of well described methods that can be used in
different countries and years to enable comparisons. Thirdly, all
multinational studies that measured content of journal advertising
were published before 1998. Since then, codes of conducts and
regulations on pharmaceutical advertising have been updated. It
will be useful to conduct a comparative international study to
provide recent comparative data on journal advertising. The study
should be conducted to compare the effects of different regulatory
frameworks. The study would provide policy makers with recent
evidence of the strengths and weaknesses of different systems. This
information is crucial for improving standards and regulations for
pharmaceutical promotion.
Most pharmaceutical markets are dominated by international
companies. These companies have their own marketing standards
which are often based on the standards set forth in the IFPMA code
of conduct [84,85]. According to the codes that are publicly
available promotional materials should encourage the appropriate
use of medicines by presenting information accurately, without
exaggeration and must follow all relevant local laws and companies
policies and procedures [84,85]. This review noted that no
independent study has been conducted to evaluate whether
companies are implementing their codes in a uniform way across
countries. It would be useful to conduct a study to compare how
advertisements for the same medicines are presented in different
countries. The study would provide the first data pertaining the
adherence of pharmaceutical companies to their own ethical codes
and local standards in the provision of medicines information in
journal advertising for international marketing communications.
Journal advertising is one among various promotional practices.
However, it has been reported that pharmaceutical companies are
cutting back print media to promote medicines and increase their
promotional activities on internet marketing [86,87] and continu-
ing medical education [88,89]. Therefore it would be beneficial to
conduct a review to examine the quality of medicines information
in internet marketing and continuing medical education.
Conclusion
Globally, pharmaceutical advertising in medical journals often
provides poor quality information. The impact of this problem on
doctors’ prescribing behaviour might be even greater in develop-
ing countries and post-Soviet Russia where access to industry-free
medicine information is limited. The results from our review
suggest the need for a global pro-active and effective regulatory
system to ensure that information provided in medical journal
advertising is supporting the quality use of medicines.
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